These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10026894)

  • 1. Stable expression of a retrovirally transferred adhesion molecule in a human tumor-specific CTL clone. Perspectives for the ex vivo manipulation of effector cells used in adoptive immunotherapy.
    Cochlovius B; Zawadzki V; Perschl A; Zöller M
    Adv Exp Med Biol; 1998; 451():345-8. PubMed ID: 10026894
    [No Abstract]   [Full Text] [Related]  

  • 2. Stable expression of a retrovirally transferred adhesion molecule in a human melanoma-specific cytotoxic T lymohocyte clone.
    Cochlovius B; Zawadzki V; Perschl A; Zöller M
    Cancer Immunol Immunother; 1998 Mar; 46(1):61-6. PubMed ID: 9520294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
    Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
    J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
    J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
    Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
    Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
    Prins RM; Odesa SK; Liau LM
    Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
    Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
    Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
    Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A
    Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells.
    Vigneron N; Ooms A; Morel S; Ma W; Degiovanni G; Van den Eynde BJ
    Tissue Antigens; 2005 Feb; 65(2):156-62. PubMed ID: 15713214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
    Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
    J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
    Clay TM; Custer MC; McKee MD; Parkhurst M; Robbins PF; Kerstann K; Wunderlich J; Rosenberg SA; Nishimura MI
    J Immunol; 1999 Feb; 162(3):1749-55. PubMed ID: 9973438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
    Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
    J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.